Prosecution Insights
Last updated: August 18, 2026

Examiner: MCKOY, QUINCY ANDRE

Tech Center 1600 • Art Units: 1625 1626 1682

This examiner grants 70% of resolved cases

Performance Statistics

70.3%
Allow Rate
+10.3% vs TC avg
131
Total Applications
+39.6%
Interview Lift
1194
Avg Prosecution Days
Based on 101 resolved cases, 2023–2026

Rejection Statute Breakdown

3.3%
§101 Eligibility
17.4%
§102 Novelty
37.5%
§103 Obviousness
27.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17297580 SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING OMEGA-3 FATTY ACID ETHYL ESTERS Non-Final OA NOVALIQ GMBH
18430679 COMPOUND OR TAUTOMER THEREOF, COMPOSITION, LAMINATE, OPTICAL FILM, IMAGE FORMING MATERIAL, AND METHOD FOR PRODUCING COMPOUND OR TAUTOMER THEREOF Non-Final OA FUJIFILM Corporation
18684143 ACID CERAMIDASE INHIBITORS AND USES THEREOF Non-Final OA The Regents of the University of California
18564968 COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA Non-Final OA Merck Patent GmbH
18570398 (1,4,5-TRISUBSTITUTED-1H-PYRAZOL-3-YL)OXY-2-ALKOXY ALKYL ACIDS AND THEIR DERIVATIVES, THEIR SALTS AND THEIR USE AS HERBICIDAL AGENTS Non-Final OA Bayer AKtiengesellschaft
18525536 METHYLQUINAZOLINONE DERIVATIVES Non-Final OA Hoffmann-La Roche Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month